Overall burden and impact on health-related quality of life associated with intravesical treatment of patients with non-muscle invasive bladder cancer in the United States.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-4877 (Electronic) Linking ISSN: 03007995 NLM ISO Abbreviation: Curr Med Res Opin Subsets: MEDLINE
    • Publication Information:
      Publication: 1995- : Newbury, Berkshire, U.K. : Informa Healthcare
      Original Publication: London, M. D. Promotions, ltd.
    • Subject Terms:
      Urinary Bladder Neoplasms*/drug therapy ; Urinary Bladder Neoplasms*/pathology ; Quality of Life*; Humans ; Male ; Female ; Middle Aged ; Administration, Intravesical ; Aged ; United States/epidemiology ; Cross-Sectional Studies ; BCG Vaccine/administration & dosage ; Adult ; Cost of Illness ; Surveys and Questionnaires ; Aged, 80 and over ; Neoplasm Invasiveness ; Gemcitabine ; Docetaxel/administration & dosage ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/administration & dosage ; Non-Muscle Invasive Bladder Neoplasms
    • Abstract:
      Background: This study aimed to describe the life impacts of intravesical therapies for non-muscle invasive bladder cancer (NMIBC) from a patient perspective.
      Methods: A cross-sectional online survey design was used. Adults with NMIBC (and no other cancer) treated intravesically in the prior 12 months were recruited from US patient online communities. Individuals participating in a clinical trial or treated with erdafitinib were excluded. Participants' treatment experiences were evaluated using a questionnaire comprising (a) custom questions reported on 11-point numerical rating scales and (b) validated patient reported outcome (PRO) measures for bladder symptom burden and work productivity.
      Results: Among 171 survey participants, most received bacillus Calmette-Guérin (BCG) (83%), intravesical gemcitabine (28%), or gemcitabine + docetaxel (13%) during the past year. Participants generally felt adequately informed about treatment, felt expectation of treatment matched actual experience, and expressed intent to complete the full treatment course and willingness to try different treatments if needed. Participants reported disease symptom burden of 42.6/72 on the NFBlSI-18 scale. Employed participants reported 51% work impairment and 59% overall work productivity loss due to NMIBC.
      Conclusions: Participants recently treated with intravesical therapies expressed intent to complete the full treatment course and willingness to try new therapies if needed. Participants reported high NMIBC symptom burden and work impairment negatively impacting their well-being, despite receiving intravesical treatment.
    • Contributed Indexing:
      Keywords: Bladder cancer; intravesical; productivity; treatment burden; unmet need; well-being
    • Accession Number:
      0 (BCG Vaccine)
      0 (Gemcitabine)
      15H5577CQD (Docetaxel)
      0W860991D6 (Deoxycytidine)
    • Publication Date:
      Date Created: 20241003 Date Completed: 20241114 Latest Revision: 20241115
    • Publication Date:
      20241115
    • Accession Number:
      10.1080/03007995.2024.2411424
    • Accession Number:
      39360373